Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®, receives approval from US FDA
피플스토리 기자
등록 2024-10-14 19:51
Dong-A ST ( (President/CEO Jae-Hun Jung, KRX: 170900) announced on October 11 that Imuldosa™ (usteki-numab-srlf/DMB-3115), a biosimilar referencing Stelara®, has won U.S. Food and Drug Administration (FDA) approval.
As its second FDA-approved biosimilar after Sivextro® (tedizolid phosphate) in 2014, the company has once again demonstrated its R&D competence.
The news comes following the FDA acceptance of the biologics license application (BLA) submitted by Ac-cord BioPharma, a wholly-owned subsidiary of Intas Pharmaceuticals, in October 2023.
Imuldosa is a biosimilar to Stelara, a blockbuster drug developed by Janssen Biotech Inc. for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn’s disease and ul-cerative colitis. It is one of the highest-grossing biopharmaceuticals generating US$10.86 billion globally (IQVIA Accumulative Sales in 2023).
Dong-A Socio Holdings and Meiji Seika Pharma began joint development for Imuldosa in 2013, and the rights for R&D and commercialization were transferred from Dong-A Socio Holdings to Dong-A ST in July 2020 for efficient project management. In July 2021, Dong-A ST and Meiji Seika Pharma signed a global li-cense agreement with Intas Pharmaceuticals, who is set to commercialize the biosimilar with its global sub-sidiaries including Accord BioPharma of the US and Accord Healthcare of the EU, UK, and Canada.
Accord Healthcare has also submitted a marketing authorisation application (MAA) to the European Medi-cines Agency (EMA) in June 2023, which was accepted in the following month of July 2023.
Dr. Jae-Hong Park, the Head of R&D at Dong-A ST commented, “This FDA approval indicates global recog-nition of Dong-A ST’s R&D excellence and global competitiveness. We look forward to a successful launch of Imuldosa in the U.S., the world’s largest pharmaceutical market, as we continue to develop innovative medicines to further strengthen our global presence.”
피플스토리
기자
여기에 광고하세요!!
많이 본 뉴스
- 1Puma Reimagines Modern Retail With Las Vegas Flagship Store Unveiling
- 2The Second Installment Featuring “Godzilla,” TOKYO GODZILLAs, to Premiere Starting Saturday, November 30!
- 3SLB awarded multi-region deepwater contracts by Shell to support capital-efficient energy development
- 4Boyd Watterson Names Don Haisch as Global Chief Financial Officer
- 5MultiBank Group Celebrates Success at Traders Fair Hong Kong 2024
- 6Pallion Group Welds Resilience and Customer Experience Into Dynamic Gold and Jewellery Business With Boomi
- 7LS전선, 국내 최대 규모 ‘해송해상풍력 프로젝트’ 해저케이블 공급 우선협상대상자 선정
- 8‘쉼 그 너머의 회복’ 서울시여성가족재단, 여성 공감·연대 위한 토크콘서트 ‘여가살롱’ 개최
- 9산불 피해 이재민에 의료급여 지원…경북·경남·울산 5개 지역 우선 시행
- 10Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
